NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Price, News & Analysis $1.84 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.88 +0.04 (+2.17%) As of 09/18/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Aptevo Therapeutics Stock (NASDAQ:APVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aptevo Therapeutics alerts:Sign Up Key Stats Today's Range$1.82▼$1.8950-Day Range$1.71▼$4.7652-Week Range$1.37▼$35.82Volume40,797 shsAverage Volume216,734 shsMarket Capitalization$3.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aptevo Therapeutics Inc. (NASDAQ:APVO) is a biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to engage the immune system and direct it against specific disease-related cells or targets. Aptevo’s pipeline is based primarily on its ADAPTIR and ADAPTIR-FLEX platform technologies, which support the development of engineered, multispecific antibodies. These programs have included investigational candidates such as APVO436, an immune-cell engager being studied in hematologic malignancies, and other compounds aimed at treating solid tumors and blood cancers. The company’s candidates remain subject to clinical and regulatory development. Aptevo was established in 2016 through a spin-off from Emergent BioSolutions, receiving certain antibody-based technologies and commercial products as part of the transaction. The company is headquartered in Seattle, Washington, and conducts its development activities through collaborations, clinical research, and regulatory programs intended to serve patients in major global healthcare markets.AI Generated. May Contain Errors. Read More Aptevo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreAPVO MarketRank™: Aptevo Therapeutics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAptevo Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aptevo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($19.30) to ($6.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptevo Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptevo Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aptevo Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.56% of the float of Aptevo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 1.93, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently increased by 44.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentAptevo Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aptevo Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.37% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by Institutions8.06% of the stock of Aptevo Therapeutics is held by institutions.Read more about Aptevo Therapeutics' insider trading history. Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APVO Stock News HeadlinesAptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average - Should You Sell?September 18 at 3:21 AM | americanbankingnews.comAptevo Reports 93% Clinical Benefit With Mipletamig Triplet In TP53-Mutated AML; Stock Down 17%September 3, 2026 | rttnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 19 at 1:00 AM | Chaikin Analytics (Ad)Aptevo reports 93% clinical benefit rate for Mipletamig triplet in TP53-mutated AMLSeptember 3, 2026 | msn.comAPVO: Focusing on Three Key Areas of DevelopmentAugust 24, 2026 | finance.yahoo.comAptevo Shareholders Back Board, Auditor and Incentive PlanAugust 21, 2026 | tipranks.comAptevo APVO Reports Q2 2026 Update With $9.8 Million CashAugust 14, 2026 | quiverquant.comQAPVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune EngagementJune 16, 2026 | finance.yahoo.comSee More Headlines APVO Stock Analysis - Frequently Asked Questions How have APVO shares performed this year? Aptevo Therapeutics' stock was trading at $9.43 on January 1st, 2026. Since then, APVO stock has decreased by 80.5% and is now trading at $1.84. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings data on Friday, August, 14th. The biotechnology company reported ($5.31) EPS for the quarter, beating analysts' consensus estimates of ($6.02) by $0.71. When did Aptevo Therapeutics' stock split? Aptevo Therapeutics shares reverse split on Wednesday, March 6th 2024.The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptevo Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA), Plug Power (PLUG) and Micron Technology (MU). Company Calendar Last Earnings8/14/2026Today9/19/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (63m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 APVO's financial health is in the Red zone, according to TradeSmith. APVO has been in this zone for over 63 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APVO CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees33Year Founded2016Profitability EPS (Trailing Twelve Months)($51.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-201.49% Return on Assets-119.21% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.42 per share Price / Book0.11Miscellaneous Outstanding Shares1,810,000Free Float1,803,000Market Cap$3.33 million OptionableNot Optionable Beta1.60 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:APVO) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
